-- Meitu Inc（香港証券取引所：1357）は、3月末時点で同社のプラットフォームの有料会員数が前年同期比30%増の1,790万人に達したと発表した。
同社の生産性向上ツールの有料加入者数は53％増の234万人に達した一方、レジャー向けアプリの加入者数は27％増の1,556万人となった。
同社の主力事業の売上高は前年同期比34.3％増の8億5200万元となった一方、その他の事業は「全体として安定」していた。
同社のAIを活用した生産性向上アプリの年間経常収益は、3月時点で5億8000万元となり、前年同期比で56％増加した。
CuFe (ASX:CUF) said an expanded scoping study on its 55%-owned Orlando project in the Northern Territory shows a net present value of around AU$705 million on a 100%-ownership basis, internal rate of return of 111%, and payback period of 10 months, according to a Wednesday Australian bourse filing.This improves to a net present value of around AU$908 million on a 100% ownership basis if spot prices as of April 8 are used, the company said.The Orlando project is part of the wider Orlando/Gecko project in which CuFe Tennant Creek holds a 55% stake and Gecko Mining, a subsidiary of Gold Valley Group, holds a 45% stake.The expanded study is based on a standalone development of the Orlando deposit, including the construction of a new processing plant, with plant purchase and installation costs of AU$86 million comprising the majority of the estimated AU$141 million total pre-production capital expenditure.The company is considering a cutback to the existing Orlando open pit, re-establishing underground operations and the installation of the plant capable of producing copper, gold, bismuth, and silver, per the filing.CuFe's shares rose past 10% in recent trading on Wednesday.
Pharmaceutical firm SSY Group (HKG:2005) said it received drug production and registration approvals for three of its products in China, according to a Hong Kong bourse filing Wednesday.The approval from China's National Medical Products Administration covers a fat-soluble vitamin injection, metformin hydrochloride tablets for type 2 diabetes, and doxazosin mesylate extended release tablets for benign prostatic hyperplasia and hypertension.
Andon Health (SHE:002432) plans to sell 9,295,000 repurchased shares through centralized bidding, according to a Wednesday disclosure on the Shenzhen bourse filing.The shares represent not more than 2% of the Chinese medical devices company's total share capital.The repurchased shares will be sold within six months.Proceeds from the sale will be used to fund business operations, including product research and development and technological investments.The company's shares fell 2% during recent trade.